PRME - Preclinical-Phase Firm Prime Medicine's Gene Editing Platform Has Potential: Analyst | Benzinga
BMO Capital Markets has initiated coverage on Prime Medicine Inc (NASDAQ: PRME), a preclinical-stage company focused on developing therapies based on prime editing.
BMO analyst's thesis centers on the distinct characteristics of prime editing, notably its high specificity and versatility, which set it apart from other gene editing methods, with the potential to provide superior and more extensive applications.
The analyst Kostas Biliouris initiates with an Outperform rating with a